XML 41 R31.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Information |
Summary of results of operations by segment | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | Contract | ​ | Intersegment | ​ | ​
Three Months Ended June 30, 2025 | Therapeutics | ​ | Research | ​ | Elimination | ​ | Total
Revenue from external customers | $ | 1,335 | ​ | $ | 442 | ​ | $ | — | ​ | $ | 1,777
Intercompany revenue | ​ | — | ​ | ​ | 3,520 | ​ | ​ | (3,520) | ​ | ​ | —
Cost of revenue | ​ | — | ​ | ​ | 3,812 | ​ | ​ | (3,297) | ​ | ​ | 515
Research and development: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Bosakitug | ​ | 2,847 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,847
ATI-2138 | ​ | 1,118 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,118
ATI-052 | ​ | 1,418 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,418
Zunsemetinib | ​ | 105 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 105
Discovery | ​ | 1,620 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,620
Total Research and development project expenses | ​ | 7,108 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7,108
Personnel | ​ | 2,984 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,984
Other research and development expense(1) | ​ | 1,580 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,580
Total research and development | ​ | 11,672 | ​ | ​ | — | ​ | ​ | (223) | ​ | ​ | 11,449
General and administrative | ​ | — | ​ | ​ | 622 | ​ | ​ | — | ​ | ​ | 622
Licensing | ​ | 1,335 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,335
Revaluation of contingent consideration | ​ | 1,500 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,500
Segment operating loss | $ | (13,172) | ​ | $ | (472) | ​ | $ | — | ​ | $ | (13,644)
Non-segment general and administrative | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 4,764
Other income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 2,979
Loss before income taxes | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | (15,429)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | Contract | ​ | Intersegment | ​ | ​
Three Months Ended June 30, 2024 | Therapeutics | ​ | Research | ​ | Elimination | ​ | Total
Revenue from external customers | $ | 2,141 | ​ | $ | 625 | ​ | $ | — | ​ | $ | 2,766
Intercompany revenue | ​ | — | ​ | ​ | 3,422 | ​ | ​ | (3,422) | ​ | ​ | —
Cost of revenue | ​ | — | ​ | ​ | 3,832 | ​ | ​ | (3,208) | ​ | ​ | 624
Research and development: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
ATI-2138 | ​ | 753 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 753
Lepzacitinib | ​ | 296 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 296
Zunsemetinib | ​ | 2,490 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,490
Discovery | ​ | 1,605 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,605
Total Research and development project expenses | ​ | 5,144 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,144
Personnel | ​ | 2,329 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,329
Other research and development expense(1) | ​ | 1,500 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,500
Total research and development | ​ | 8,973 | ​ | ​ | — | ​ | ​ | (214) | ​ | ​ | 8,759
General and administrative | ​ | — | ​ | ​ | 1,020 | ​ | ​ | — | ​ | ​ | 1,020
Licensing | ​ | 1,285 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,285
Revaluation of contingent consideration | ​ | 200 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 200
Segment operating loss | $ | (8,317) | ​ | $ | (805) | ​ | $ | — | ​ | $ | (9,122)
Non-segment general and administrative | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 3,732
Other income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1,868
Loss before income taxes | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | (10,986)
| (1) | Other segment items for the Therapeutics segment consist primarily of the following research and development expenses: stock-based compensation, depreciation and amortization, and regulatory.
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | Contract | ​ | Intersegment | ​ | ​
Six Months Ended June 30, 2025 | Therapeutics | ​ | Research | ​ | Elimination | ​ | Total
Revenue from external customers | $ | 2,345 | ​ | $ | 887 | ​ | $ | — | ​ | $ | 3,232
Intercompany revenue | ​ | — | ​ | ​ | 6,955 | ​ | ​ | (6,955) | ​ | ​ | —
Cost of revenue | ​ | — | ​ | ​ | 7,529 | ​ | ​ | (6,508) | ​ | ​ | 1,021
Research and development: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Bosakitug | ​ | 6,231 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 6,231
ATI-2138 | ​ | 2,926 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,926
ATI-052 | ​ | 2,037 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,037
Zunsemetinib | ​ | 216 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 216
Discovery | ​ | 2,966 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,966
Total Research and development project expenses | ​ | 14,376 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 14,376
Personnel | ​ | 5,911 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,911
Other research and development expense(1) | ​ | 3,193 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,193
Total research and development | ​ | 23,480 | ​ | ​ | — | ​ | ​ | (447) | ​ | ​ | 23,033
General and administrative | ​ | — | ​ | ​ | 1,522 | ​ | ​ | — | ​ | ​ | 1,522
Licensing | ​ | 2,345 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,345
Revaluation of contingent consideration | ​ | 1,800 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,800
Segment operating loss | $ | (25,280) | ​ | $ | (1,209) | ​ | $ | — | ​ | $ | (26,489)
Non-segment general and administrative | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 10,003
Other income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 5,978
Loss before income taxes | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | (30,514)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(In thousands) | ​ | ​ | Contract | ​ | Intersegment | ​ | ​
Six Months Ended June 30, 2024 | Therapeutics | ​ | Research | ​ | Elimination | ​ | Total
Revenue from external customers | $ | 3,882 | ​ | $ | 1,281 | ​ | $ | — | ​ | $ | 5,163
Intercompany revenue | ​ | — | ​ | ​ | 7,087 | ​ | ​ | (7,087) | ​ | ​ | —
Cost of revenue | ​ | — | ​ | ​ | 8,073 | ​ | ​ | (6,640) | ​ | ​ | 1,433
Research and development: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
ATI-2138 | ​ | 815 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 815
Lepzacitinib | ​ | 1,368 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,368
Zunsemetinib | ​ | 4,514 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,514
Discovery | ​ | 3,145 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,145
Total Research and development project expenses | ​ | 9,842 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 9,842
Personnel | ​ | 7,032 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7,032
Other research and development expense(1) | ​ | 2,177 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,177
Total research and development | ​ | 19,051 | ​ | ​ | — | ​ | ​ | (447) | ​ | ​ | 18,604
General and administrative | ​ | — | ​ | ​ | 2,128 | ​ | ​ | — | ​ | ​ | 2,128
Licensing | ​ | 2,316 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,316
Revaluation of contingent consideration | ​ | 3,000 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,000
Segment operating loss | $ | (20,485) | ​ | $ | (1,833) | ​ | $ | — | ​ | $ | (22,318)
Non-segment general and administrative | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 9,468
Other income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 3,859
Loss before income taxes | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | (27,927)
| (1) | Other segment items for the Therapeutics segment consist primarily of the following research and development expenses: stock-based compensation, depreciation and amortization, and regulatory.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration